FMC (FMC) Up 9.8% Since Last Earnings Report: Can It Continue?

06.03.25 17:31 Uhr

Werte in diesem Artikel
Aktien

37,05 EUR 2,35 EUR 6,77%

43,51 EUR -0,14 EUR -0,32%

Indizes

PKT PKT

2.003,1 PKT 30,0 PKT 1,52%

2.077,0 PKT 28,9 PKT 1,41%

23.419,5 PKT 338,5 PKT 1,47%

8.971,0 PKT 129,7 PKT 1,47%

1.767,6 PKT 33,3 PKT 1,92%

2.975,3 PKT 0,8 PKT 0,03%

2.143,9 PKT 0,6 PKT 0,03%

213,4 PKT 6,2 PKT 3,00%

568,5 PKT 4,2 PKT 0,75%

12.264,7 PKT 192,8 PKT 1,60%

23.217,0 PKT 34,0 PKT 0,15%

23.235,0 PKT 29,5 PKT 0,13%

9.061,1 PKT 128,5 PKT 1,44%

17.740,6 PKT 246,7 PKT 1,41%

1.854,4 PKT -8,4 PKT -0,45%

5.743,6 PKT -99,0 PKT -1,69%

It has been about a month since the last earnings report for FMC (FMC). Shares have added about 9.8% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is FMC due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts. FMC Corp's Earnings Surpass Estimates, Revenues Miss in Q4FMC reported a loss of 13 cents for fourth-quarter 2024. This is in contrast with earnings of $8.77 reported in the year-ago quarter.Barring one-time items, adjusted earnings per share were $1.79, beating the Zacks Consensus Estimate of $1.61.Revenues were roughly $1.22 billion in the quarter, up around 6.8% from the year-ago quarter’s level. The top line fell short of the Zacks Consensus Estimate of $1.32 billion.FMC's fourth-quarter revenues were driven by a 15% increase in volume, with growth reported in several countries, especially the United States.Regional Sales PerformanceIn North America, sales increased 23% year over year to $340 million in the quarter, driven by higher volume. The figure missed the Zacks Consensus Estimate of $347.5 million.Latin America sales saw a 10% year-over-year decline to $390 million in the reported quarter, as higher volumes were partly offset by a low-single-digit price decline. The figure missed the Zacks Consensus Estimate of $516.9 million.In Asia, revenues rose 10% year over year, totaling $307 million due to higher volumes. The figure beat the Zacks Consensus Estimate of $273.7 million.EMEA experienced an 18% year-over-year sales upside, reaching $188 million in the reported quarter. Higher volumes in EMEA resulted in sales growth, excluding currency impacts. The Plant Health business improved over the previous year. The figure beat the Zacks Consensus Estimate of $183 million.FY24 ResultsFor the full year, FMC reported revenues amounting to roughly $4.25 billion, marking a 5.4% decrease from the previous year. On a reported basis, the company posted full-year net income of $341.1 million, reflecting a 74.1% decrease. Consolidated earnings per share were $2.72, down 74.2% year over year. FinancialsThe company had cash and cash equivalents of $357.3 million at the end of the quarter, up roughly 18.1% year over year. Long-term debt was around $3.03 billion, up around 0.1% year over year.GuidanceRevenues for the first quarter are projected to be in the $750 million to $800 million range, a 16% decrease at the midpoint from the same period in 2024. Volume is likely to fall as customers in various countries continue to cut inventories, and retailers and growers make cautious purchases in an environment of low commodity prices. Adjusted EBITDA is estimated to be in the $105 million to $125 million range, a 28% decrease at the midpoint compared to the prior-year quarter, as lower expenses somewhat offset lower price and currency headwinds. Adjusted EPS is estimated to be in the range of 5 cents to 15 cents, representing a 72% fall at the midpoint against the first quarter of 2024 due to the reduction in adjusted EBITDA.Revenues for full-year 2025 are expected to be in the $4.15 billion to $4.35 billion range, roughly steady at the midpoint and up 3% after accounting for about $110 million in lost revenues from the GSS business divestiture. Full-year adjusted EBITDA is estimated to be between $870 million and $950 million, up 1% from the previous year at the midpoint and 4% after accounting for roughly $25 million in lost EBITDA from the GSS sale. The adjusted EPS for 2025 is estimated to be $3.26 to $3.70 per share, which is consistent with the previous year at the midpoint. Full-year free cash flow is projected to be $200 million to $400 million, a $314 million decrease from 2024 at the midpoint, as the free cash flow conversion normalizes following the outsized recovery in 2024.How Have Estimates Been Moving Since Then?In the past month, investors have witnessed a downward trend in estimates review.The consensus estimate has shifted -96.2% due to these changes.VGM ScoresCurrently, FMC has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with an F. However, the stock was allocated a grade of B on the value side, putting it in the top 40% for this investment strategy.Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. It's no surprise FMC has a Zacks Rank #5 (Strong Sell). We expect a below average return from the stock in the next few months.Only $1 to See All Zacks' Buys and SellsWe're not kidding.Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 256 positions with double- and triple-digit gains in 2024 alone.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report FMC Corporation (FMC): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

Ausgewählte Hebelprodukte auf FMC

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf FMC

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Fresenius Medical Care (FMC) St.

Wer­bung

Analysen zu Fresenius Medical Care (FMC) St.

DatumRatingAnalyst
04.03.2025Fresenius Medical Care (FMC) St UnderperformJefferies & Company Inc.
04.03.2025Fresenius Medical Care (FMC) St Market-PerformBernstein Research
27.02.2025Fresenius Medical Care (FMC) St HoldWarburg Research
27.02.2025Fresenius Medical Care (FMC) St KaufenDZ BANK
26.02.2025Fresenius Medical Care (FMC) St HoldDeutsche Bank AG
DatumRatingAnalyst
27.02.2025Fresenius Medical Care (FMC) St KaufenDZ BANK
25.02.2025Fresenius Medical Care (FMC) St BuyGoldman Sachs Group Inc.
30.01.2025Fresenius Medical Care (FMC) St BuyJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
28.01.2025Fresenius Medical Care (FMC) St BuyJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
21.01.2025Fresenius Medical Care (FMC) St BuyGoldman Sachs Group Inc.
DatumRatingAnalyst
04.03.2025Fresenius Medical Care (FMC) St Market-PerformBernstein Research
27.02.2025Fresenius Medical Care (FMC) St HoldWarburg Research
26.02.2025Fresenius Medical Care (FMC) St HoldDeutsche Bank AG
25.02.2025Fresenius Medical Care (FMC) St Market-PerformBernstein Research
25.02.2025Fresenius Medical Care (FMC) St HoldWarburg Research
DatumRatingAnalyst
04.03.2025Fresenius Medical Care (FMC) St UnderperformJefferies & Company Inc.
26.02.2025Fresenius Medical Care (FMC) St UnderweightJP Morgan Chase & Co.
25.02.2025Fresenius Medical Care (FMC) St UnderperformJefferies & Company Inc.
25.02.2025Fresenius Medical Care (FMC) St UnderweightJP Morgan Chase & Co.
14.02.2025Fresenius Medical Care (FMC) St UnderweightJP Morgan Chase & Co.

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Fresenius Medical Care (FMC) St. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"